加科思-B(01167)发布公告，公司董事会已获公司一致行动人士成员告知，于2025年7月24日至7月29 日，彼等已于公开市场按7.16港元的平均每股价格继续买入合计6.09万股公司股份(。紧随此次持股增加 之后，截至本公告日期，该一致行动人士成员近期合计买入115.53万股，一致行动人士共持有公司2.01 亿股股份，约占公司已发行股份总数的25.36%。 ...

加科思-B(01167)发布公告，公司董事会已获公司一致行动人士成员告知，于2025年7月24日至7月29 日，彼等已于公开市场按7.16港元的平均每股价格继续买入合计6.09万股公司股份(。紧随此次持股增加 之后，截至本公告日期，该一致行动人士成员近期合计买入115.53万股，一致行动人士共持有公司2.01 亿股股份，约占公司已发行股份总数的25.36%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 一致行動人士進一步增持股份 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本公司一致行動人士（「一致行動人士」） 權益變動的情況。 本公司董事會（「董事會」）已獲公司一致行動人士成員告知，於2025年7月24日至7月29日， 彼等已於公開市場按7.16港元的平均每股價格繼續買入合計60,900股本公司股份（「股份」）。 緊隨此次持股增加之後，截至本公告日期，該一致行動人士成員近期合計買入1,155,300股， 一致行動人士共持有本公司200,755,285股股份，約佔本公司已發行股份總數的25.36%。 上述一致行動人士成員表示對本公司的整體發展前景、增長潛力及其股份的長期投資價 值充滿信心。在遵守適用法律及監管規定的前提 ...

Core Viewpoint - On July 28, 10 Hong Kong-listed companies conducted share buybacks, totaling 12.86 million shares and an amount of 10.74 million HKD [1][2] Group 1: Buyback Details - China Eastern Airlines repurchased 2.5 million shares for 7.50 million HKD, with a highest price of 3.030 HKD and a lowest price of 2.970 HKD, accumulating a total buyback amount of 613.45 million HKD for the year [1][2] - Carrot repurchased 160,000 shares for 816,000 HKD, with a highest price of 5.250 HKD and a lowest price of 5.080 HKD, accumulating a total buyback amount of 7.50 million HKD for the year [1][2] - Miniso repurchased 15,000 shares for 557,900 HKD, with a highest price of 37.200 HKD and a lowest price of 37.150 HKD, accumulating a total buyback amount of 313.34 million HKD for the year [1][2] Group 2: Buyback Rankings - The highest buyback amount on July 28 was from China Eastern Airlines at 7.50 million HKD, followed by Carrot at 816,000 HKD, and Miniso among others [1][2] - In terms of buyback quantity, Ying Group had the highest with 9.20 million shares, followed by China Eastern Airlines with 2.5 million shares and Maple Leaf Education with 428,000 shares [1][2]

Summary of Key Points Core Viewpoint - Several companies, including China Eastern Airlines and Miniso, conducted share buybacks on July 28, 2025, with China Eastern Airlines having the largest buyback amount of 749.83 million yuan for 2.5 million shares [1]. Group 1: Buyback Details - China Eastern Airlines (00670) repurchased 2.5 million shares for 749.83 million yuan, with a total annual buyback of 109 million shares, representing 2.106% of its total share capital [2]. - Carrot (N24025) repurchased 160,000 shares for 816,000 yuan, with a total annual buyback of 823,500 shares, accounting for 1.480% of its total share capital [2]. - Miniso (09896) repurchased 15,000 shares for 557,900 yuan, with a total annual buyback of 3.2419 million shares, representing 0.261% of its total share capital [2]. - Ying Group (00397) repurchased 9.2 million shares for 487,600 yuan, with a total annual buyback of 89.8 million shares, accounting for 3.780% of its total share capital [2]. - Modern Dental (03600) repurchased 100,000 shares for 424,600 yuan, with a total annual buyback of 4.1 million shares, representing 0.437% of its total share capital [2]. - Gacos (B) (01167) repurchased 47,400 shares for 354,500 yuan, with a total annual buyback of 110,400 shares, accounting for 0.014% of its total share capital [2]. - Lihong Inspection (01586) repurchased 76,000 shares for 235,600 yuan, with a total annual buyback of 1.484 million shares, representing 2.507% of its total share capital [2]. - Maple Leaf Education (01317) repurchased 428,000 shares for 158,400 yuan, with a total annual buyback of 42.554 million shares, accounting for 1.432% of its total share capital [2]. - Wanka Yilian (01762) repurchased 200,000 shares for 146,000 yuan, with a total annual buyback of 17.814 million shares, representing 1.006% of its total share capital [2]. - Hong Kong Food Investment (00060) repurchased 130,000 shares for 60,200 yuan, with a total annual buyback of 3.932 million shares, accounting for 1.515% of its total share capital [2].

表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年7月15日 | 788 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 本公司董事會（「董事會」）已獲公司一致行動人士成員告知，於2025年7月21日至7月22日， 彼等已於公開市場按7.05港元的平均每股價格繼續買入合計240,000股本公司股份（「股份」）。 緊隨此次持股增加之後，截至本公告日期，一致行動人士共持有本公司200,694,385股股份， 約佔本公司已發行股份總數的25.35%。 上述一致行動人士成員表示對本公司的整體發展前景、增長潛力及其股份的長期投資價 值充滿信心。在遵守適用法律及監管規定的前提下，並不排除其可能適時進一步增持本 公司股份。 根據本公司所得資料及據董事會所知，本次增持已遵照適用法律、規則及條文（包括《香 港聯合交易所有限公司證券上 ...

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook for investment opportunities [3]. Core Insights - The new centralized procurement regulations emphasize "stability in clinical use, quality assurance, prevention of collusion, and countering excessive competition," which are expected to promote the long-term healthy development of the industry [2][32]. - The report suggests focusing on recently launched innovative products, high-quality raw material suppliers, and key products that have passed the consistency evaluation for generic drugs [2][32]. Summary by Sections Market Review - The pharmaceutical and biotechnology index increased by 4% this week, outperforming the CSI 300 index by 2.91 percentage points, ranking second in industry performance [11]. - Year-to-date, the pharmaceutical and biotechnology index has risen by 16.59%, also surpassing the CSI 300 index by 13.45 percentage points [11]. - The chemical pharmaceutical sector showed the highest growth this week at 6.86%, while traditional Chinese medicine had the lowest decline at 0.88% [16][18]. Individual Stock Performance - In the A-share market, 397 out of 474 pharmaceutical stocks rose, with the top five performers being: - Borui Pharmaceutical (+42.35%) - Lisheng Pharmaceutical (+41.68%) - Nanxin Pharmaceutical (+34.95%) - Aosai Kang (+32.77%) - Yipin Hong (+32.13%) [22]. - In the Hong Kong market, 96 out of 106 pharmaceutical stocks increased, with the top performers including: - Clover Biopharma-B (+63.79%) - Lepu Biopharma-B (+62.04%) - Deqi Pharmaceutical-B (+47.04%) [25]. Industry News and Policies - The 11th batch of national centralized drug procurement was officially launched, including 55 varieties across various therapeutic areas, focusing on clinical needs and market realities [28]. - The new procurement rules are more refined, requiring production experience and quality control capabilities from manufacturers, which will help ensure drug quality and promote industry standardization [28]. - The establishment of the "Commercial Insurance Innovative Drug Directory" marks a significant step in building a multi-tiered medical security system, providing new economic support for innovative drug development [28]. Key Company Announcements - Heng Rui Pharmaceutical reported positive results from its GLP-1/GIP dual receptor agonist HRS9531 in a Phase III weight loss study, with an average weight reduction of 19.2% in the treatment group [29][31]. - The report highlights various corporate actions, including stock incentive plans and capital increases by several companies, indicating active corporate governance and strategic investments in the sector [36].

Core Viewpoint - 加科思药业 has seen significant management confidence through recent share buybacks and purchases, indicating a belief in the undervaluation of the company and its pipeline potential [1][4] Group 1: Shareholder Actions - 加科思药业 announced that its concerted parties have recently increased their holdings by 854,400 shares at an average price of HKD 5.88 per share, totaling over HKD 5 million [1] - The company does not rule out the possibility of further share purchases in the future [1] - The management's high-level purchases reflect a strong belief in the company's value and pipeline confidence, especially after a 427% increase in stock price year-to-date [1] Group 2: Product Pipeline and Market Potential - The company's most notable product, the KRAS inhibitor JAB-23E73, has entered Phase I trials in China and the U.S., with a global sales peak potential of USD 12.1 billion, particularly in pancreatic and non-small cell lung cancers [2] - JAB-23E73 is a small molecule oral drug with promising pharmacokinetics and significant anti-tumor activity, showing a cost advantage over competitors [3] - 加科思's market capitalization is currently at HKD 5 billion, significantly lower than Revolution Medicine's USD 7 billion, indicating substantial upside potential [3] Group 3: Financial Outlook and Revenue Generation - The approval of the KRAS G12C inhibitor, 戈来雷塞, marks a critical milestone for 加科思, expected to generate stable cash flow through its commercialization [4] - 戈来雷塞 is priced at approximately HKD 38,000 per month, with a potential market size of HKD 6 billion based on patient demographics and market share estimates [4] - The strategic partnership with 艾力斯 for sales in China could yield approximately HKD 200 million annually from milestone and sales sharing, providing solid performance support for the company's current valuation [5] Group 4: Future Developments - The SHP2 inhibitor JAB-3312 is the first of its kind to enter Phase III trials, with potential implications for first-line treatment of non-small cell lung cancer, which could trigger additional milestones for 艾力斯 and become a new revenue source [6]

加科思-B公告，于2025年7月16日至7月18日，一致行动人士在公开市场以5.88港元的平均每股价格买入 合计85.44万股。此次增持后，一致行动人士共持有公司2亿股股份，约占已发行股份总数的25.32%。 ...